Cancer clinical trials in the region Bretagne

271 currently recruiting clinical trials
Region Bretagne
Phase 3 Pancreas cancer #NCT07252232 #2025-523495-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy
Excluded previous treatments at localized stage
Targeted therapy
3 recruiting sites
Revolution Medicines, Inc.
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07419295
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 3 Amyloidosis #NCT07207811 #2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3 Colon cancer Rectal cancer #NCT07222800 #2025-523521-18-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
3 recruiting sites
Pfizer
Phase 3 Lung cancer #NCT06312137 #2023-508012-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie B (Sensible au platine avec traitement antérieur par Parpi)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Eli Lilly et compagnie
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie C (Sensible au platine naive de traitement par Parpi
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
9 recruiting sites
Eli Lilly et compagnie
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie A (Résistant au platine)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Eli Lilly et compagnie
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
32 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris